Compare Uber Technologies Inc (UBER) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uber Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Uber Technologies Inc trades at $70.65 (market cap $143.47B), while State Street SPDR S&P Biotech ETF trades at $150.44 (market cap $10.11B). The key difference: Uber Technologies Inc is far larger — about 14.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Uber Technologies Inc for 88 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| UBER | XBI | |
|---|---|---|
Market Cap | $143.47B | $10.11B |
Volume | 14,430,657 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $99.72 | $169.55 |
52-Week Low | $65.94 | $104.99 |
Typical Hold Time | 88 Days | 37 Days |
Enterprise Value | $152.81B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uber trades at $68.45, down 0.91% on the day, with a bearish technical signal despite strong fundamentals. The company reported $52.02B revenue in 2025 with $10.05B net income, maintaining robust growth from $44.0B revenue in 2024. Recent expansion includes the Costco delivery partnership reaching 47 states, while CEO Dara Khosrowshahi purchased $10 million in shares, signaling confidence.
Uber presents a compelling growth story with expanding profitability and dominant market position, though technical indicators suggest near-term pressure. The consensus price target of $104.72 implies 53% upside, supported by 82.5% analyst buy ratings. Key risks include robotaxi competition and projected negative cash flow in 2026.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
